Age-Related Macular Degeneration

While the prevalence of blindness due to age-related macular degeneration decreased globally from 2000 to 2020, researchers warn that the social and economic impact of AMD may grow as the population ages.

In this video, Rishi P. Singh, MD, discusses results from part 1 of the phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy, presented at the ASRS annual meeting in Stockholm.

Healio’s articles from the American Society of Retina Specialists meeting have covered long-term improvements with Luxturna and macular hole closure rates with different pars plana vitrectomy techniques.

Optometry in the 21st century has moved strongly toward evidence-based medicine, with the American Optometric Association even publishing a 14-step process to assist in the development of an evidence-based practice.

In this Healio Video Perspective from the ASRS annual meeting, Dilraj Grewal, MD, FASRS, discusses eyes that developed macular neovascularization in the GATHER trials.

In this Healio Video Perspective from the ASRS meeting, Christina Y. Weng, MD, MBA, FASRS, of Baylor College of Medicine in Houston discusses 96-week safety and tolerability data for aflibercept 8 mg.

In a paper recently published in Retina, an expert panel of retina specialists provided guidance on suprachoroidal space injection.

In this Healio Video Perspective from the ASRS meeting, Laurent Fischer, MD, of Adverum Biotechnologies discusses 26-week results from the phase 2 LUNA study investigating Ixo-vec for neovascular age-related macular degeneration.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, discusses efficacy and safety data for the port delivery system ahead of its reintroduction.

SEATTLE — In this video, Eleonora M. Lad, MD, PhD, discusses presentations from the ARVO annual meeting on real-world use of faricimab and the use of pegcetacoplan in the treatment of geographic atrophy.